28 results on '"Zielinski C"'
Search Results
2. Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study
- Author
-
Kahan, Z, Gil-Gil, M, Ruiz-Borrego, M, Carrasco, EM, Ciruelos, EM, Munoz, M, De Las Heras, BB, Vila, MM, Anton, A, Casas, M, Calvo, L, de la Haba, J, Ramos, M, Alvarez-Lopez, I, Gal-Yam, E, Gautier, E, Corsaro, M, Rodrigalvarez, G, Zielinski, C, and Jimenez, MM
- Published
- 2020
3. COP27 Climate Change Conference: urgent action needed for Africa and the world.
- Author
-
Atwoli L, Erhabor GE, Gbakima AA, Haileamlak A, Kayembe Ntumba JM, Kigera J, Laybourn-Langton L, Mash B, Muhia J, Mavis Mulaudzi F, Ofori-Adjei D, Okonofua F, Rashidian A, El-Adawy M, Sidibé S, Snouber A, Tumwine J, Sahar Yassien M, Yonga P, Zakhama L, and Zielinski C
- Subjects
- Humans, Africa, Climate Change
- Published
- 2024
- Full Text
- View/download PDF
4. COP27 Climate Change Conference: urgent action needed for Africa and the world.
- Author
-
Atwoli L, Erhabor GE, Gbakima AA, Haileamlak A, Ntumba JK, Kigera J, Laybourn-Langton L, Mash B, Muhia J, Mulaudzi FM, Ofori-Adjei D, Okonofua F, Rashidian A, El-Adawy M, Sidibé S, Snouber A, Tumwine J, Yassien MS, Yonga P, Zakhama L, and Zielinski C
- Published
- 2023
- Full Text
- View/download PDF
5. COP27 Climate Change Conference: urgent action needed for Africa and the world.
- Author
-
Laybourn-Langton L, Muhia J, El-Adawy M, Sidibé S, and Zielinski C
- Subjects
- Humans, Africa epidemiology, Climate Change
- Published
- 2023
- Full Text
- View/download PDF
6. COP27 Climate Change Conference: Urgent Action Needed for Africa and the World.
- Author
-
Ntumba JK, Laybourn-Langton L, Muhia J, Rashidian A, El-Adawy M, Sidibé S, and Zielinski C
- Subjects
- Humans, Africa epidemiology, Climate Change
- Published
- 2023
- Full Text
- View/download PDF
7. COP27 Climate Change Conference: urgent action needed for Africa and the world.
- Author
-
Atwoli L, Erhabor GE, Gbakima AA, Haileamlak A, Kayembe Ntumba JM, Kigera J, Laybourn-Langton L, Mash B, Muhia J, Mavis Mulaudzi F, Ofori-Adjei D, Okonofua F, Rashidian A, El-Adawy M, Sidibé S, Snouber A, Tumwine J, Sahar Yassien M, Yonga P, Zakhama L, and Zielinski C
- Subjects
- Humans, Africa, Climate Change
- Published
- 2022
- Full Text
- View/download PDF
8. COP27 Climate Change Conference: urgent action needed for Africa and the world.
- Author
-
Laybourn-Langton L, Muhia J, El-Adawy M, Sidibé S, and Zielinski C
- Subjects
- Humans, Africa, Climate Change
- Published
- 2022
- Full Text
- View/download PDF
9. COP27 Climate Change Conference: urgent action needed for Africa and the world: Wealthy nations must step up support for Africa and vulnerable countries in addressing past, present and future impacts of climate change.
- Author
-
Atwoli L, Erhabor GE, Gbakima AA, Haileamlak A, Ntumba JK, Kigera J, Laybourn-Langton L, Mash B, Muhia J, Mulaudzi FM, Ofori-Adjei D, Okonofua F, Rashidian A, El-Adawy M, Sidibé S, Snouber A, Tumwine J, Yassien MS, Yonga P, Zakhama L, and Zielinski C
- Abstract
Competing Interests: Conflict of interest: In the interest of transparency the authors wish to declare the following roles and relationships: J.K. is the Ex-Officio, President and Secretary of the Kenya Orthopedic Association; P.Y. been paid to speak or participate at events by Novartis, bioMerieux and Pfizer; C.Z. is a paid consultant for the UK Health Alliance on Climate Change; J.M. is an unpaid board member of the International Working Group for Health systems strengthening; D.O.-A. has a relationship with GLICO Healthcare Ltd. The authors declare no further conflicts of interest beyond those inherent in the editorial roles listed above.
- Published
- 2022
- Full Text
- View/download PDF
10. Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis.
- Author
-
Cufer T, Ciuleanu TE, Berzinec P, Galffy G, Jakopovic M, Jassem J, Jovanovic D, Mihaylova Z, Ostoros G, Thallinger C, Zemanova M, and Zielinski C
- Subjects
- Europe, Humans, Medical Oncology, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Pharmaceutical Preparations
- Abstract
Background: Treatment of non-small cell lung cancer (NSCLC) improved substantially in the last decades. Novel targeted and immune-oncologic drugs were introduced into routine treatment. Despite accelerated development and subsequent drug registrations by the European Medicinal Agency (EMA), novel drugs for NSCLC are poorly accessible in Central and Eastern European (CEE) countries., Material and Methods: The Central European Cooperative Oncology Group conducted a survey among experts from 10 CEE countries to provide an overview on the availability of novel drugs for NSCLC and time from registration to reimbursement decision in their countries., Results: Although first-generation epidermal growth factor receptor tyrosine kinase inhibitors were reimbursed and available in all countries, for other registered therapies-even for ALK inhibitors and checkpoint inhibitors in first-line-there were apparent gaps in availability and/or reimbursement. There was a trend for better availability of drugs with longer time from EMA marketing authorization. Substantial differences in access to novel drugs among CEE countries were observed. In general, the availability of drugs is not in accordance with the Magnitude of Clinical Benefit Scale (MCBS), as defined by the European Society for Medical Oncology (ESMO). Time spans between drug registrations and national decisions on reimbursement vary greatly, from less than 3 months in one country to more than 1 year in the majority of countries., Conclusion: The access to novel drugs for NSCLC in CEE countries is suboptimal. To enable access to the most effective compounds within the shortest possible time, reimbursement decisions should be faster and ESMO MCBS should be incorporated into decision making., (© 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.)
- Published
- 2020
- Full Text
- View/download PDF
11. Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group.
- Author
-
Ryska A, Buiga R, Fakirova A, Kern I, Olszewski W, Plank L, Seiwerth S, Toth E, Zivka E, Thallinger C, Zielinski C, and Brcic L
- Subjects
- Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung therapy, Europe, Humans, Lung Neoplasms pathology, Lung Neoplasms therapy, Precision Medicine, Surveys and Questionnaires, Carcinoma, Non-Small-Cell Lung epidemiology, Health Expenditures standards, Lung Neoplasms epidemiology
- Abstract
This article analyzes the availability of different diagnostic procedures of non-small cell lung cancer (NSCLC) and the reimbursement landscape of drugs for NSCLC in countries of central and southeastern Europe (CEE). A survey was conducted by the Central European Cooperative Oncology Group. Results of the survey show that both availability and reimbursement of diagnoses of molecular alterations in NSCLC, the detection of which is essential for therapeutic decisions, varies widely between countries of CEE. Not only is "reflex" testing often substituted by analyses performed only "on demand," but reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. It was concluded that a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. IMPLICATIONS FOR PRACTICE: This article provides an overview of the limitations in lung cancer treatment in countries of central and southeastern Europe, as well as the reimbursement status of various lung cancer treatment regimens in these countries, which directly impacts treatment options., Competing Interests: Disclosures of potential conflicts of interest may be found at the end of this article., (© AlphaMed Press 2018.)
- Published
- 2018
- Full Text
- View/download PDF
12. RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
- Author
-
Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, and de Vries EGE
- Subjects
- United States, United States Food and Drug Administration, Antineoplastic Agents, Drug Approval
- Published
- 2018
- Full Text
- View/download PDF
13. Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients.
- Author
-
Königsbrügge O, Posch F, Riedl J, Reitter EM, Zielinski C, Pabinger I, and Ay C
- Subjects
- Aged, Biomarkers, Tumor blood, Female, Humans, Inflammation mortality, Inflammation pathology, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasms mortality, Neoplasms pathology, Risk Factors, Venous Thromboembolism mortality, Venous Thromboembolism pathology, Inflammation blood, Neoplasms blood, Serum Albumin metabolism, Venous Thromboembolism blood
- Abstract
Background: In cancer patients, reduced serum albumin has been described as a marker for global declining health and poor prognosis. Our aim was to investigate the association of albumin concentrations with the occurrence of venous thromboembolism (VTE) and mortality in patients with cancer., Methods: This investigation was performed in the framework of the Vienna Cancer and Thrombosis Study (CATS), a prospective observational cohort study. We included 1,070 patients with active cancer and assayed serum albumin from venous blood taken at study inclusion. Risk for occurrence of VTE was calculated in a proportional subdistribution hazard regression model with respect to competing risk of death and adjusted for cancer site, leukocyte count, estimated glomerular filtration rate, and cholinesterase., Results: Patients (630 males [58.9%] and 440 females [41.1%]) were observed for a median of 723 days. During follow-up, 90 VTE events (8.4%) and 396 deaths (37.0%) occurred. The median albumin was 41.3 g/L (25th-75th percentile, 37.6-44.2). Patients with albumin levels below the 75th percentile had a 2.2-fold increased risk of VTE (95% confidence interval [CI] 1.09-4.32), as well as a 2.3-fold increased risk of death (95% CI 1.68-3.20) compared with patients with albumin above the 75th percentile., Conclusion: Decreased serum albumin levels in cancer patients were significantly associated with increased risk of VTE and mortality. Serum albumin, a marker of a cancer patient's overall prognosis, could be considered for risk assessment of important clinical outcomes such as VTE and mortality., Implications for Practice: Cancer patients are at increased risk of venous thromboembolism (VTE). In this prospective cohort study of 1,070 cancer patients, decreased serum albumin was a marker for risk of VTE and mortality, independent of kidney or liver function and inflammation markers. The study identified a group of patients with high risk of cancer-associated VTE and a reduced prognosis who may benefit from supportive therapy such as primary VTE prophylaxis., (©AlphaMed Press.)
- Published
- 2016
- Full Text
- View/download PDF
14. Public perception of cancer care in Poland and Austria.
- Author
-
Jȩdrzejewski M, Thallinger C, Mrozik M, Kornek G, Zielinski C, and Jassem J
- Subjects
- Austria, Data Collection, European Union, Family psychology, Humans, Neoplasms psychology, Poland, Attitude to Health, Neoplasms epidemiology, Patients psychology
- Abstract
Background: We compared the public perception of cancer care in Poland and Austria. Both countries are members of the European Union (EU) but reflect two extremes in health-related per capita spending. Recently, the EUROCARE-5 study reported on very discrepant cancer outcomes between the two countries., Methods: A one-time survey was conducted to compare the public perception of cancer treatment in Poland and Austria. In total, 3,649 subjects, representing the general population, cancer patients, and cancer patients' family members, were surveyed., Results: In both countries, cancer was considered the most challenging problem of the health care system, and health care was indicated as the most important issue influencing political election decisions. Polish compared with Austrian cancer patients gave a significantly lower positive assessment of overall cancer treatment efficacy and detection methods. Cancer cure rates estimated by Polish and Austrian citizens were 29% and 44%, respectively. The majority of all citizens interviewed thought that cancer patients should have access to all available registered cancer drugs. However, only 18% of Poles versus 62% of Austrians agreed with the notion that the available cancer treatment in their countries is of a standard comparable to that of other EU countries. Consequently, 24% of Poles and 7% of Austrians identified financial status, age, gender, and residence as factors influencing the availability of cancer treatments., Conclusion: In both countries, cancer is considered the most challenging problem of the health care system, and health care issues may strongly influence decisions for political elections. Vast differences in the two populations' perceptions of cancer care reflect actual cancer outcomes and the national per capita spending on health-related issues., (©AlphaMed Press.)
- Published
- 2015
- Full Text
- View/download PDF
15. Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas.
- Author
-
Thaler J, Ay C, Kaider A, Reitter EM, Haselböck J, Mannhalter C, Zielinski C, Marosi C, and Pabinger I
- Subjects
- Adult, Aged, Biomarkers, Central Nervous System Neoplasms blood, Female, Follow-Up Studies, Glioma blood, Humans, Male, Middle Aged, Proportional Hazards Models, Prospective Studies, Risk Factors, Venous Thromboembolism complications, Central Nervous System Neoplasms complications, Glioma complications, P-Selectin analysis, Platelet Count, Venous Thromboembolism diagnosis
- Abstract
Background: High-grade gliomas (HGGs) are among the most prothrombotic of malignancies., Methods: We performed a prospective study to investigate 11 potential biomarkers for prediction of venous thromboembolism (VTE) in newly diagnosed HGG patients who had undergone a neurosurgical intervention. In addition, we tested 2 VTE risk assessment models (RAMs). The strongest predictors of VTE, which were identified by statistical forward selection, were used for the first RAM. The parameters used for the second RAM were both predictive of VTE and available in routine clinical practice., Results: One hundred forty-one HGG patients were included in this study, and 24 (17%) of them developed VTE during follow-up. An association with the risk of future VTE was found for the following parameters: leukocyte count, platelet count, sP-selectin, prothrombin-fragment 1 + 2, FVIII activity, and D-dimer. The first RAM included low platelet count (<25th percentile of the study population) and elevated sP-selectin (≥75th percentile). The cumulative VTE probability after 12 months was 9.7% for score 0 (n = 76), 18.9% for score 1 (n = 59), and 83.3% for score 2 (n = 6). The second RAM included low platelet count (<25th percentile), elevated leukocyte count, and elevated D-dimer (≥75th percentile). The probability of VTE was 3.3% for score 0 (n = 63), 23.0% for score 1 (n = 53), and 37.7% for score 2 (n = 22) or score 3 (n = 3)., Conclusions: We identified biomarkers suitable for assessing the VTE risk in newly diagnosed HGG patients. The application of 2 RAMs allowed identification of patients at high risk of developing VTE. We could also define patients at low risk of VTE, who would most probably not benefit from extended primary thromboprophylaxis., (© The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2014
- Full Text
- View/download PDF
16. Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients.
- Author
-
Reitter EM, Ay C, Kaider A, Pirker R, Zielinski C, Zlabinger G, and Pabinger I
- Subjects
- Adult, Aged, Aged, 80 and over, Colonic Neoplasms immunology, Colonic Neoplasms mortality, Female, Follow-Up Studies, Humans, Lung Neoplasms immunology, Lung Neoplasms mortality, Male, Middle Aged, Pancreatic Neoplasms immunology, Pancreatic Neoplasms mortality, Prognosis, Prospective Studies, Survival Analysis, Venous Thromboembolism immunology, Venous Thromboembolism mortality, Biomarkers, Tumor metabolism, Colonic Neoplasms diagnosis, Interleukins metabolism, Lung Neoplasms diagnosis, Pancreatic Neoplasms diagnosis, Venous Thromboembolism diagnosis
- Abstract
Cytokines have been found to be elevated in cancer patients and have been associated with worse prognosis in single tumour entities. We investigated the association of eight different cytokines with venous thromboembolism (VTE) and prognosis in cancer patients. The Vienna Cancer and Thrombosis Study (CATS), a prospective study, includes patients with newly diagnosed tumour or disease progression. Patients with an overt infection are excluded. Study end-points are VTE, death, loss to follow-up or study completion. Interleukin (IL) serum levels were measured using the xMAP technology developed by Luminex. Among 726 included patients, no associations between IL levels and VTE were found, with the exception of a trend for IL-1β and IL-6 in pancreatic cancer. Elevated levels of IL-6 [as continuous variable per double increase hazard ratio (HR) = 1·07, 95% confidence interval (CI) = 1·027-1·114, P = 0·001, IL-8 (HR = 1·12, 95% CI = 1·062-1·170, P < 0·001) and IL-11 (HR = 1·37, 95% CI = 1·103-1·709, P = 0·005] were associated with worse survival. In subgroup analyses based on tumour type, colon carcinoma patients, who had higher IL-6 levels, showed a shorter survival (HR = 2·405, 95% CI = 1·252-4·618, P = 0·008). A significant association of elevated IL-10 levels with a decrease in survival (HR = 1·824, 95% CI = 1·098-3·031, P = 0·020) was seen among patients with lung cancer. No correlation between VTE and IL levels was found, but higher IL-6, IL-8 and IL-11 levels were associated with worse survival in cancer patients. Further, elevated IL-6 levels might be a prognostic marker in colorectal cancer and elevated IL-10 levels in lung cancer patients., (© 2014 British Society for Immunology.)
- Published
- 2014
- Full Text
- View/download PDF
17. A catalyst for change: the European cancer Patient's Bill of Rights.
- Author
-
Lawler M, Le Chevalier T, Murphy MJ Jr, Banks I, Conte P, De Lorenzo F, Meunier F, Pinedo HM, Selby P, Armand JP, Barbacid M, Barzach M, Bergh J, Bode G, Cameron DA, de Braud F, de Gramont A, Diehl V, Diler S, Erdem S, Fitzpatrick JM, Geissler J, Hollywood D, Højgaard L, Horgan D, Jassem J, Johnson PW, Kapitein P, Kelly J, Kloezen S, La Vecchia C, Löwenberg B, Oliver K, Sullivan R, Tabernero J, Van de Velde CJ, Wilking N, Wilson R, Zielinski C, Zur Hausen H, and Johnston PG
- Subjects
- Europe epidemiology, European Union, Healthcare Disparities, Humans, Neoplasms epidemiology, Neoplasms therapy, Patient Rights legislation & jurisprudence, Patient-Centered Care legislation & jurisprudence
- Published
- 2014
- Full Text
- View/download PDF
18. Bevacizumab treatment for advanced breast cancer.
- Author
-
Alvarez RH, Guarneri V, Icli F, Johnston S, Khayat D, Loibl S, Martin M, Zielinski C, Conte P, and Hortobagyi GN
- Subjects
- Bevacizumab, Female, Humans, Angiogenesis Inhibitors therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Breast Neoplasms drug therapy, Vascular Endothelial Growth Factor A metabolism
- Abstract
Significant advances in the treatment of patients with breast cancer have been made in the past 10 years. The current systemic treatment of breast cancer is characterized by the discovery of multiple cancer targets leading to treatments that are more sophisticated and specific than conventional cytotoxic chemotherapy. Two classes of compounds that have helped improve clinical outcomes are small molecules and monoclonal antibodies targeting specific tyrosine kinase receptors. Many novel targets have been discovered, and parallel multiple approaches to anticancer therapy have recently emerged from the literature. One promising strategy is targeting the proangiogenic vascular endothelial growth factors (VEGFs), either by ligand sequestration (preventing VEGF receptor binding) or inhibiting downstream receptor signaling. Bevacizumab, a monoclonal antibody directed against VEGF, has been shown to improve the efficacy of taxanes in frontline treatment of patients with metastatic breast cancer. This review outlines the most promising breast cancer studies using bevacizumab combined with traditional cytotoxic agents in advanced breast cancer. In addition, we discuss the current indications reviewed by the Oncologic Drug Advisory Committee and define our vision of how the benefit of patient clinical trials should be measured.
- Published
- 2011
- Full Text
- View/download PDF
19. Venous thromboembolism and survival in patients with high-grade glioma.
- Author
-
Simanek R, Vormittag R, Hassler M, Roessler K, Schwarz M, Zielinski C, Pabinger I, and Marosi C
- Subjects
- Adult, Aged, Body Mass Index, Combined Modality Therapy, Female, Follow-Up Studies, Glioma pathology, Glioma surgery, Humans, Male, Middle Aged, Probability, Survival Analysis, Thromboembolism mortality, Time Factors, Venous Thrombosis mortality, Glioma complications, Glioma mortality, Thromboembolism etiology, Venous Thrombosis etiology
- Abstract
Patients with malignancy, particularly patients with high-grade glioma (HGG; WHO grade III/IV), have an increased risk of venous thromboembolism (VTE). It has been suggested that VTE predicts survival in cancer patients. The aim of our study was to investigate the occurrence of symptomatic VTE and its impact on survival in patients with HGG. Consecutive patients (n = 63; 36 female, 27 male; median age, 58 years) who had neurosurgical intervention between October 2003 and December 2004 were followed after surgery until October 2005. Objectively confirmed VTE was recorded as an event. All patients had received thrombosis prophylaxis with low-molecular-weight heparin (LMWH) during the immediate postoperative period. Subsequently, 56 patients received radiochemotherapy, 6 radiotherapy, and 1 chemotherapy only. Patients were followed over a median time period of 348 days. Fifteen patients (24%) developed VTE. Pulmonary embolism was diagnosed in nine patients (60%) and was fatal twice. The cumulative probability of VTE was 21% after three months and 26% after 12 months. The highest frequency of VTE was observed in patients with biopsy and subtotal tumor resection (n = 37; multivariate hazard ratio, 3.58; 95% CI = 0.98-13.13; P = 0.054) compared with patients with total resection. Survival did not significantly differ among patients with and without VTE and was 53% after 12 months in both groups. Patients with HGG, particularly those with biopsy and subtotal resection, are at high risk to develop VTE postoperatively. Thrombosis was not associated with a significant reduction of survival.
- Published
- 2007
- Full Text
- View/download PDF
20. What are the current standards of care and recent developments in the management of breast cancer?
- Author
-
Cameron D, Bell R, Aapro M, and Zielinski C
- Subjects
- Antineoplastic Combined Chemotherapy Protocols standards, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Clinical Trials as Topic, Female, Humans, Breast Neoplasms drug therapy, Patient Care Management standards, Patient Care Management trends
- Published
- 2006
- Full Text
- View/download PDF
21. Inhibition of metastases by anticoagulants.
- Author
-
Hejna M, Raderer M, and Zielinski CC
- Subjects
- Animals, Anticoagulants pharmacology, Clinical Trials as Topic, Colorectal Neoplasms drug therapy, Colorectal Neoplasms pathology, Drug Evaluation, Drug Screening Assays, Antitumor, Fibrinolytic Agents pharmacology, Fibrinolytic Agents therapeutic use, Humans, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Neoplasm Metastasis drug therapy, Platelet Aggregation Inhibitors pharmacology, Platelet Aggregation Inhibitors therapeutic use, Anticoagulants therapeutic use, Neoplasm Metastasis prevention & control
- Abstract
Metastasis involves several distinct steps, including one in which the tumor cell, after entry into the bloodstream, comes to rest in a capillary located at the distant site where a metastatic tumor will ultimately form. Components of the blood-clotting pathway may contribute to metastasis by trapping cells in capillaries or by facilitating adherence of cells to capillary walls. Conceivably, anticoagulants could interfere with this step in the metastatic process. In this review, we have summarized current knowledge on the interaction of malignant cells, clotting factors, and anticoagulants. We used computerized (MEDLINE) and manual searches to identify studies done in humans, in animals, and in in vitro systems that were published in English between 1952 and 1998. We found many reports that the formation of metastatic tumors could be inhibited by heparin, a vitamin K antagonist (warfarin), and inhibitors of platelet aggregation (prostacyclin and dipyridamole). Despite these encouraging preliminary results and a compelling biochemical rationale, only limited information exists on the clinical use of anticoagulants for the prevention or treatment of metastatic cancer because there have been so few controlled and prospectively randomized studies on this topic. In view of the preliminary results, anticoagulants may hold promise for the prevention and treatment of metastases. We believe that larger controlled investigations are strongly warranted to evaluate the clinical potential of anticoagulants for the prevention and treatment of metastases in humans.
- Published
- 1999
- Full Text
- View/download PDF
22. Gemcitabine-induced hemolytic uremic syndrome: a case report.
- Author
-
Brodowicz T, Breiteneder S, Wiltschke C, and Zielinski CC
- Subjects
- Carcinoma, Non-Small-Cell Lung drug therapy, Deoxycytidine adverse effects, Hemolytic-Uremic Syndrome complications, Hemolytic-Uremic Syndrome pathology, Humans, Kidney drug effects, Kidney pathology, Kidney Failure, Chronic chemically induced, Lung Neoplasms drug therapy, Male, Middle Aged, Gemcitabine, Antimetabolites, Antineoplastic adverse effects, Deoxycytidine analogs & derivatives, Hemolytic-Uremic Syndrome chemically induced
- Published
- 1997
- Full Text
- View/download PDF
23. Modulation of leucocyte locomotion by interleukin-1.
- Author
-
Zielinski CC, Pesau B, Kalinowski W, and Müller C
- Subjects
- Caseins pharmacology, Cells, Cultured, Humans, Interleukin-1 pharmacology, Neutrophils physiology, Zymosan pharmacology, Chemotaxis, Leukocyte, Interleukin-1 immunology
- Abstract
The influence of interleukin-1 (IL-1) upon leucocyte locomotion in vitro was studied, using either casein or zymosan-activated serum (ZAS) as chemotaxigens. A pre-incubation of polymorphonuclear cells (PMNC) with ultrapure (purity 99%) human IL-1 (1 U/ml) for 2 and 5 h followed by a washing step resulted in a significant decrease in leucocyte locomotion against casein (P less than 0.0005 and P less than 0.01, respectively), but not against ZAS (P greater than 0.1). Moreover, the direct addition of this IL-1 preparation to leucocyte locomotion assays without pre-incubation produced a similar and significant inhibition of leucocyte locomotion directed against casein (P less than 0.05). This inhibitory effect could not be augmented further by higher concentrations of ultrapure IL-1. In order to exclude the effect of possibly contaminating cytokines in the ultrapure IL-1 preparation used, additional assays with recombinant human IL-1 (rIL-1) alpha and rIL-1 beta (1 U/ml) were performed to investigate their influence upon leucocyte locomotion. It was found that both rIL-1 alpha and rIL-1 beta inhibited leucocyte locomotion directed against casein significantly (P less than 0.005). Similar to the previous experiments, leucocyte locomotion could not be further inhibited by higher concentrations (10 U/ml) or rIL-1. Thus, both ultrapure and rIL-1 were found to have the ability to inhibit leucocyte locomotion in vitro.
- Published
- 1990
- Full Text
- View/download PDF
24. Functional activity of peripheral mononuclear cells in cystic fibrosis: antibodies and plaque formation.
- Author
-
Götz M, Zielinski CC, Ahmad R, and Eibl M
- Subjects
- Adolescent, Adult, Antibodies, Bacterial biosynthesis, Antibodies, Viral biosynthesis, Child, Child, Preschool, Female, Hemolytic Plaque Technique, Humans, Immunoglobulins analysis, Male, Antibody-Producing Cells immunology, Cystic Fibrosis immunology, Leukocytes immunology
- Abstract
Chronic pulmonary infection is known to constitute a major complication of cystic fibrosis (CF). In order to determine whether a defect of antibody formation is associated with this clinical finding, we have investigated antibody production on the cellular level by using a haemolytic plaque forming cell (PFC) assay. The ability of peripheral mononuclear cells (MNC) derived from patients with CF to form PFC upon stimulation by pokeweed mitogen was significantly decreased as compared to healthy control individuals (P less than 0 . 01). Levels of serum immunoglobulins of the G, A, and M classes and of sheep red blood cell agglutinating antibodies were estimated as well, but no correlation was obtained between these parameters and the number of PFC in patients with CF.
- Published
- 1982
25. Con A-induced suppressor cells in children with acute lymphoblastic leukaemia.
- Author
-
Eibl M, Krepler P, Schmidmeier W, Zielinski C, and Winterleitner H
- Subjects
- Acute Disease, Adolescent, Child, Child, Preschool, Female, Humans, Lymphocyte Activation, Lymphocytes immunology, Male, Concanavalin A pharmacology, Leukemia, Lymphoid immunology, T-Lymphocytes, Regulatory immunology
- Abstract
The function of Con A stimulation was investigated in patients with ALL in remission and in patients with ALL in the acute phase of the disease as compared to healthy controls. Suppression of the Con A response brought about by autologous Con A-activated cells was significantly lower in ALL patients in remission (mean value 29.33%) and in the acute phase (mean value 10%) than in the controls (mean value 64.86%). Suppression of the Con A stimulation of control lymphocytes by Con A-activated homologous cells of ALL patients had a mean value of 51.65%. This was significantly higher than the suppression obtained by the same ALL cells in the autologous system and of the same order of magnitude as the suppression obtained by control Con A-activated cells on control Con A stimulation (57.67%). Suppression of the Con a response of ALL lymphocytes produced by control Con A-activated cells was 23.17% and comparable to healthy controls. These results demonstrate that the function of Con A-induced suppression is significantly lower in ALL patients. They further indicate that at least two cell types are involved in this kind of suppression in humans.
- Published
- 1980
26. Prinzmetal's angina during cyclophosphamide therapy.
- Author
-
Stefenelli T, Zielinski CC, Mayr H, and Scoheithauer W
- Subjects
- Aged, Cyclophosphamide administration & dosage, Dose-Response Relationship, Drug, Drug Administration Schedule, Electrocardiography, Female, Humans, Angina Pectoris, Variant chemically induced, Carcinoma, Squamous Cell drug therapy, Cyclophosphamide adverse effects, Lymphoma drug therapy, Maxillary Neoplasms drug therapy, Neoplasms, Multiple Primary drug therapy
- Abstract
The first case of cyclophosphamide-induced myocardial ischaemia with electrocardiographically documented ST-segment elevation, T-wave inversion, arrhythmias, angina pectoris and cardiac decompensation is reported. The data suggest that cyclophosphamides induces myocardial ischaemia by eliciting coronary artery spasm.
- Published
- 1988
- Full Text
- View/download PDF
27. Plaque-forming cells in human cord blood: studies on T and B cell function.
- Author
-
Eibl M, Zielinski CC, Ahmad R, Steurer F, and Rockenschaub A
- Subjects
- Adult, Cell Survival, Cells, Cultured, Hemolytic Plaque Technique, Humans, Infant, Newborn, Leukocyte Count, T-Lymphocytes, Regulatory immunology, B-Lymphocytes immunology, Fetal Blood immunology, T-Lymphocytes immunology
- Abstract
Fewer plaque-forming cells (PFC) were found in the cord blood than in adult blood. B cells of newborns seem to be functionally mature. T cells of newborns provide enough help but exert increased suppressor activity.
- Published
- 1980
28. Serum associated leucocyte locomotion inhibition and leucocyte motility in malignant melanoma: effect of BCG treatment.
- Author
-
Zielinski C, Pehamberger H, Endler AT, and Knapp W
- Subjects
- Cell Movement, Chemotaxis, Leukocyte, Female, Humans, Male, Melanoma therapy, Neoplasm Staging, Prognosis, BCG Vaccine therapeutic use, Leukocytes immunology, Macrophage Migration-Inhibitory Factors blood, Melanoma immunology
- Published
- 1979
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.